Logo image of YCBD

CBDMD INC (YCBD) Stock Fundamental Analysis

USA - NYSEARCA:YCBD - US12482W4087 - Common Stock

1.43 USD
-0.05 (-3.38%)
Last: 10/8/2025, 8:21:11 PM
1.41 USD
-0.02 (-1.4%)
After Hours: 10/8/2025, 8:21:11 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to YCBD. YCBD was compared to 196 industry peers in the Pharmaceuticals industry. YCBD has a bad profitability rating. Also its financial health evaluation is rather negative. YCBD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year YCBD has reported negative net income.
YCBD had a negative operating cash flow in the past year.
In the past 5 years YCBD reported 4 times negative net income.
In the past 5 years YCBD always reported negative operating cash flow.
YCBD Yearly Net Income VS EBIT VS OCF VS FCFYCBD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

YCBD's Return On Assets of -38.06% is in line compared to the rest of the industry. YCBD outperforms 45.92% of its industry peers.
With a Return On Equity value of -625.23%, YCBD is not doing good in the industry: 79.59% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -38.06%
ROE -625.23%
ROIC N/A
ROA(3y)-140.25%
ROA(5y)-86.1%
ROE(3y)-308.88%
ROE(5y)-187.27%
ROIC(3y)N/A
ROIC(5y)N/A
YCBD Yearly ROA, ROE, ROICYCBD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

YCBD has a better Gross Margin (62.35%) than 69.90% of its industry peers.
YCBD's Gross Margin has been stable in the last couple of years.
YCBD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.98%
GM growth 5Y0.07%
YCBD Yearly Profit, Operating, Gross MarginsYCBD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

3

2. Health

2.1 Basic Checks

YCBD does not have a ROIC to compare to the WACC, probably because it is not profitable.
YCBD has more shares outstanding than it did 1 year ago.
YCBD has more shares outstanding than it did 5 years ago.
YCBD has a worse debt/assets ratio than last year.
YCBD Yearly Shares OutstandingYCBD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
YCBD Yearly Total Debt VS Total AssetsYCBD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -21.85, we must say that YCBD is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of YCBD (-21.85) is worse than 82.65% of its industry peers.
YCBD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -21.85
ROIC/WACCN/A
WACC8.57%
YCBD Yearly LT Debt VS Equity VS FCFYCBD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

YCBD has a Current Ratio of 0.63. This is a bad value and indicates that YCBD is not financially healthy enough and could expect problems in meeting its short term obligations.
YCBD has a worse Current ratio (0.63) than 89.80% of its industry peers.
A Quick Ratio of 0.36 indicates that YCBD may have some problems paying its short term obligations.
With a Quick ratio value of 0.36, YCBD is not doing good in the industry: 93.37% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.63
Quick Ratio 0.36
YCBD Yearly Current Assets VS Current LiabilitesYCBD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

3

3. Growth

3.1 Past

YCBD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.77%, which is quite impressive.
YCBD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.35%.
Measured over the past years, YCBD shows a decrease in Revenue. The Revenue has been decreasing by -3.80% on average per year.
EPS 1Y (TTM)71.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-132.81%
Revenue 1Y (TTM)-19.35%
Revenue growth 3Y-24.06%
Revenue growth 5Y-3.8%
Sales Q2Q%-10.96%

3.2 Future

Based on estimates for the next years, YCBD will show a very strong growth in Earnings Per Share. The EPS will grow by 40.90% on average per year.
Based on estimates for the next years, YCBD will show a small growth in Revenue. The Revenue will grow by 0.98% on average per year.
EPS Next Y92.04%
EPS Next 2Y40.9%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-2.84%
Revenue Next 2Y0.98%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
YCBD Yearly Revenue VS EstimatesYCBD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
YCBD Yearly EPS VS EstimatesYCBD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2023 2024 2025 2026 0 -500 -1K -1.5K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

YCBD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year YCBD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
YCBD Price Earnings VS Forward Price EarningsYCBD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
YCBD Per share dataYCBD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

YCBD's earnings are expected to grow with 40.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.9%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

YCBD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CBDMD INC

NYSEARCA:YCBD (10/8/2025, 8:21:11 PM)

After market: 1.41 -0.02 (-1.4%)

1.43

-0.05 (-3.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)12-16 2025-12-16/amc
Inst Owners5.44%
Inst Owner Change0%
Ins Owners1.71%
Ins Owner Change9.97%
Market Cap12.74M
Analysts82.86
Price Target2.04 (42.66%)
Short Float %1.16%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.64%
Min EPS beat(2)-16.42%
Max EPS beat(2)41.71%
EPS beat(4)3
Avg EPS beat(4)44.78%
Min EPS beat(4)-16.42%
Max EPS beat(4)112.65%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.4%
Min Revenue beat(2)-9.45%
Max Revenue beat(2)-3.36%
Revenue beat(4)1
Avg Revenue beat(4)-4.22%
Min Revenue beat(4)-9.45%
Max Revenue beat(4)2.96%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)72.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.65
P/FCF N/A
P/OCF N/A
P/B 19.14
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.03
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS2.2
BVpS0.07
TBVpS-0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.06%
ROE -625.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.35%
FCFM N/A
ROA(3y)-140.25%
ROA(5y)-86.1%
ROE(3y)-308.88%
ROE(5y)-187.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.98%
GM growth 5Y0.07%
F-Score4
Asset Turnover1.79
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25%
Cap/Sales 1.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.63
Quick Ratio 0.36
Altman-Z -21.85
F-Score4
WACC8.57%
ROIC/WACCN/A
Cap/Depr(3y)26.48%
Cap/Depr(5y)59.22%
Cap/Sales(3y)1.56%
Cap/Sales(5y)1.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-132.81%
EPS Next Y92.04%
EPS Next 2Y40.9%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-19.35%
Revenue growth 3Y-24.06%
Revenue growth 5Y-3.8%
Sales Q2Q%-10.96%
Revenue Next Year-2.84%
Revenue Next 2Y0.98%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y80.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y95.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.38%
OCF growth 3YN/A
OCF growth 5YN/A